iconoclast/cabel - My comments are in general only.

Since all of the BoM data is blinded there has been nothing to talk about, other than the 9 DSMB reports for the last 3.5 years. Beginning about 14 to 15 months ago there have been a number of articles and presentations at different conferences about CKD and dementia/Alzheimer's just because they could talk about that. Most of that info was taken from previous trials other than ages, sexes and baselines from patients in this trial. If that is considered focusing on the secondary outcomes I could understand where noretreat's comments came from.

At this point in time apabetalone is RVX's only drug prospect in a trial. In order to keep the interest of investors and potential investors the company needs to talk about whatever they can. I don't consider this as a change of focus to the secondaries but more of a topic to talk about because they can.

Just my two cents worth.

tada